Literature DB >> 26596782

The Bromodomain: A New Target in Emerging Epigenetic Medicine.

Steven G Smith1, Ming-Ming Zhou1.   

Abstract

The bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that has the ability to recognize acetylated lysine residues. This activity allows bromodomains to play a vital role in many acetylation-mediated protein-protein interactions in the cell, ranging from substrate recruitment for histone acetyltransferases (HATs) to aiding in multiple-protein complex assembly for gene transcriptional activation or suppression in chromatin. In recent years, considerable efforts have been made to develop chemical inhibitors of these bromodomains in an effort to probe their cellular functions. Potent and selective inhibitors have been extensively developed for one group of the bromodomain family termed BET proteins that consist of tandem bromodomains followed by an extra terminal domain. Drug developers are actively designing inhibitors of other bromodomains and working to move the most successful inhibitors into the clinic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26596782      PMCID: PMC7295032          DOI: 10.1021/acschembio.5b00831

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  71 in total

1.  Targeting MYC dependence in cancer by inhibiting BET bromodomains.

Authors:  Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

2.  Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors.

Authors:  Emmanuel H Demont; Chun-wa Chung; Rebecca C Furze; Paola Grandi; Anne-Marie Michon; Chris Wellaway; Nathalie Barrett; Angela M Bridges; Peter D Craggs; Hawa Diallo; David P Dixon; Clement Douault; Amanda J Emmons; Emma J Jones; Bhumika V Karamshi; Kelly Locke; Darren J Mitchell; Bernadette H Mouzon; Rab K Prinjha; Andy D Roberts; Robert J Sheppard; Robert J Watson; Paul Bamborough
Journal:  J Med Chem       Date:  2015-07-09       Impact factor: 7.446

Review 3.  The general transcription machinery and general cofactors.

Authors:  Mary C Thomas; Cheng-Ming Chiang
Journal:  Crit Rev Biochem Mol Biol       Date:  2006 May-Jun       Impact factor: 8.250

4.  Target structure-based discovery of small molecules that block human p53 and CREB binding protein association.

Authors:  Lois Resnick-Silverman; Sherry Yan; Shiraz Mutjaba; Wen-Jun Liu; Lei Zeng; James J Manfredi; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2006-01

5.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer.

Authors:  Jian Shi; Yifan Wang; Lei Zeng; Yadi Wu; Jiong Deng; Qiang Zhang; Yiwei Lin; Junlin Li; Tiebang Kang; Min Tao; Elena Rusinova; Guangtao Zhang; Chi Wang; Haining Zhu; Jun Yao; Yi-Xin Zeng; B Mark Evers; Ming-Ming Zhou; Binhua P Zhou
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

6.  Structural insights into human KAP1 PHD finger-bromodomain and its role in gene silencing.

Authors:  Lei Zeng; Kyoko L Yap; Alexey V Ivanov; Xueqi Wang; Shiraz Mujtaba; Olga Plotnikova; Frank J Rauscher; Ming-Ming Zhou
Journal:  Nat Struct Mol Biol       Date:  2008-05-18       Impact factor: 15.369

7.  brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2.

Authors:  J W Tamkun; R Deuring; M P Scott; M Kissinger; A M Pattatucci; T C Kaufman; J A Kennison
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

8.  LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.

Authors:  Peter G K Clark; Lucas C C Vieira; Cynthia Tallant; Oleg Fedorov; Dean C Singleton; Catherine M Rogers; Octovia P Monteiro; James M Bennett; Roberta Baronio; Susanne Müller; Danette L Daniels; Jacqui Méndez; Stefan Knapp; Paul E Brennan; Darren J Dixon
Journal:  Angew Chem Int Ed Engl       Date:  2015-04-13       Impact factor: 15.336

9.  The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.

Authors:  C Wong; S V Laddha; L Tang; E Vosburgh; A J Levine; E Normant; P Sandy; C R Harris; C S Chan; E Y Xu
Journal:  Cell Death Dis       Date:  2014-10-09       Impact factor: 8.469

10.  Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.

Authors:  Peiling Chen; Apirat Chaikuad; Paul Bamborough; Marcus Bantscheff; Chas Bountra; Chun-Wa Chung; Oleg Fedorov; Paola Grandi; David Jung; Robert Lesniak; Matthew Lindon; Susanne Müller; Martin Philpott; Rab Prinjha; Catherine Rogers; Carolyn Selenski; Cynthia Tallant; Thilo Werner; Timothy M Willson; Stefan Knapp; David H Drewry
Journal:  J Med Chem       Date:  2015-04-06       Impact factor: 7.446

View more
  42 in total

1.  BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice.

Authors:  Kalung Cheung; Geming Lu; Rajal Sharma; Adam Vincek; Ruihua Zhang; Alexander N Plotnikov; Fan Zhang; Qiang Zhang; Ying Ju; Yuan Hu; Li Zhao; Xinye Han; Jamel Meslamani; Feihong Xu; Anbalagan Jaganathan; Tong Shen; Hongfa Zhu; Elena Rusinova; Lei Zeng; Jiachi Zhou; Jianjun Yang; Liang Peng; Michael Ohlmeyer; Martin J Walsh; David Y Zhang; Huabao Xiong; Ming-Ming Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

Review 2.  Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.

Authors:  Victoria Jeffers; Chunlin Yang; Sherri Huang; William J Sullivan
Journal:  Microbiol Mol Biol Rev       Date:  2017-01-11       Impact factor: 11.056

Review 3.  Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.

Authors:  Roodolph St Pierre; Cigall Kadoch
Journal:  Curr Opin Genet Dev       Date:  2017-04-06       Impact factor: 5.578

4.  Drug discovery: Doubling down on BET inhibition.

Authors:  Dafydd Owen
Journal:  Nat Chem Biol       Date:  2016-11-15       Impact factor: 15.040

5.  Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.

Authors:  Beth E Zucconi; Jessica L Makofske; David J Meyers; Yousang Hwang; Mingxuan Wu; Mitzi I Kuroda; Philip A Cole
Journal:  Biochemistry       Date:  2019-04-11       Impact factor: 3.162

6.  Discovery and lead identification of quinazoline-based BRD4 inhibitors.

Authors:  Shyh-Ming Yang; Daniel J Urban; Makoto Yoshioka; Jeffrey W Strovel; Steven Fletcher; Amy Q Wang; Xin Xu; Pranav Shah; Xin Hu; Matthew D Hall; Ajit Jadhav; David J Maloney
Journal:  Bioorg Med Chem Lett       Date:  2018-08-31       Impact factor: 2.823

7.  Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay.

Authors:  Tian Lu; Jun-Chi Hu; Wen-Chao Lu; Jie Han; Hong Ding; Hao Jiang; Yuan-Yuan Zhang; Li-Yan Yue; Shi-Jie Chen; Hua-Liang Jiang; Kai-Xian Chen; Hui-Fang Chai; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

8.  NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.

Authors:  Jun-Lan Yu; Tian-Tian Chen; Chen Zhou; Fu-Lin Lian; Xu-Long Tang; Yi Wen; Jing-Kang Shen; Ye-Chun Xu; Bing Xiong; Nai-Xia Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-05-30       Impact factor: 6.150

9.  Structural Insights into Histone Crotonyl-Lysine Recognition by the AF9 YEATS Domain.

Authors:  Qiang Zhang; Lei Zeng; Chengcheng Zhao; Ying Ju; Tsuyoshi Konuma; Ming-Ming Zhou
Journal:  Structure       Date:  2016-08-18       Impact factor: 5.006

10.  Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.

Authors:  Beth E Zucconi; Birgit Luef; Wei Xu; Ryan A Henry; Ilana M Nodelman; Gregory D Bowman; Andrew J Andrews; Philip A Cole
Journal:  Biochemistry       Date:  2016-07-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.